Table 3.
Main urinary rifamycin SV PK parameters of the different regimensa
| Treatment | Interval (h) | Xu (ng) | dXu/dt (ng/h) | ΣXu (ng) | ΣXu (% of dose) |
|---|---|---|---|---|---|
| Single oral 400-mg dose under fasting conditions | 0–6 | <0.1 | <0.1 | 3,966.1 ± 6,166.3 | 0.0010 ± 0.0015 |
| 6–12 | 1,612.8 ± 3,338.4 | 268.8 ± 556.4 | |||
| 12–24 | 2,353.4 ± 3,221.4 | 196.1 ± 268.5 | |||
| Single oral 400-mg dose under fed conditions | 0–6 | <0.1 | <0.1 | 1,500.5 ± 3,049.1 | 0.0004 ± 0.0008 |
| 6–12 | 103.2 ± 335.7 | 17.2 ± 55.9 | |||
| 12–24 | 1,397.3 ± 2,990.5 | 116.4 ± 249.2 | |||
| Oral 800-mg dose (200 mg q.i.d.) | 0–3 | 1,873.9 ± 1,405.8 | 624.6 ± 468.6 | 7,172.7 ± 4,180.0 | 0.0036 ± 0.0021 |
| 3–6 | 1,611.1 ± 931.2 | 537.0 ± 310.4 | |||
| 6–12 | 3,687.7 ± 2,377.6 | 614.6 ± 396.3 | |||
| Oral 800-mg dose (400 mg b.i.d.) | 0–3 | 3,216.9 ± 2,437.2 | 1,072.3 ± 812.4 | 10,914.5 ± 5,309.3 | 0.0027 ± 0.0013 |
| 3–6 | 2,713.3 ± 1,249.5 | 904.4 ± 416.5 | |||
| 6–12 | 4,984.3 ± 3,029.6 | 830.7 ± 504.9 |
a
Values are means ± SD. Shown are the amount of excretion (Xu) (expressed in ng and as a percentage), the rate of excretion (dXu/dt), and the total amount of excretion (ΣXu) (expressed in ng and as a percentage) after a single dose (n = 22) and multiple oral doses (n = 12) of rifamycin SV MMX (200-mg tablets).